{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-22-000033","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2022-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.903717+00:00","generated_at":"2026-06-26T14:43:44.571533+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sera Prognostics Q4 2021 revenue $26k, net loss $12.5M; losses widen as commercial ops scale","bullets":["Q4 2021 revenue rose to $26k from $6k YoY; net loss of $12.5M vs $5.4M.","Full-year 2021 revenue $82k, total operating expenses $35.5M (up from $18M).","Cash and securities totaled $139.9M as of Dec 31, 2021.","CMS set Medicare payment rate of $750 for PreTRM test; added to NASDAQ Biotechnology Index.","R&D spend increased to $3.1M in Q4; SG&A jumped to $9.5M on higher headcount and public company costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-22-000033","json":"https://secwatch.observer/filing/0001534969-22-000033.json","markdown":"https://secwatch.observer/filing/0001534969-22-000033.md","text":"https://secwatch.observer/filing/0001534969-22-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000033/0001534969-22-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000033/sera-20220329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T14:43:44.571533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}